BioSpace News Archive

Castle Biosciences to Present Data at the 18th European Association of Dermato Oncology (EADO) Congress.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has granted Marketing Authorization for the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include children with cystic fibrosis (CF) ages 6 through 11 years who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced data demonstrating that MN-166 (ibudilast) prevents metastasis in a uveal melanoma (UM) animal model was published in the journal Molecular Cancer Research.

GATC Health, a biotech company revolutionizing drug discovery and disease prediction using artificial intelligence and advanced multiomics, announced it has filed a patent application for an innovative new prodrug designed to safely cross the blood-brain barrier for cancer treatment.

NGM Biopharmaceuticals, Inc. announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at the following upcoming virtual investor conferences.

Alkermes plc will host a conference call and webcast presentation at 8:00 a.m. ET on Wednesday, April 27, 2022 to discuss the company’s first quarter financial results.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has granted Marketing Authorization for the expanded use of PrTRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include children with cystic fibrosis (CF) ages 6 through 11 years who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

The global healthcare regulatory affairs market is predicted to grow at a CAGR of 8.9% during the forecast period from 2021 to 2030.

Albany NY, United States: The remote patient monitoring devices market has been estimated to experience significant growth prospects in the forthcoming years.

Albany NY, United States: According to the report, the global pressure relief devices market was valued at US$ 2.6 Bn in 2019 and is projected to expand at a high CAGR from 2020 to 2030.